EUVIMEDEUVIMED entdecken
Leitlinie

Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline

Nadine Tung iD, Charité Ricker, Hans Messersmith iD, Judith Balmaña iD, Susan Domchek iD, Elena Martinez Stoffel, Khaldoun Almhanna, Banu Arun iD, Yanin Chavarri-Guerra iD, Stephanie A Cohen iD, Deborah Cragun, Katherine D Crew iD und 9 weitere

Journal of Clinical Oncology · 20.07.2024 · 42 (21) · 2599-2615

DOI: 10.1200/jco.24.00662 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.07.2024. Verfasst von Nadine Tung und 20 weiteren Autor:innen. Beteiligte Einrichtung: Beth Israel Deaconess Medical Center, Sharon, MA. Hauptthemen laut MEDLINE: Genetic Testing, Neoplasms, Germ-Line Mutation, Genetic Predisposition to Disease. Die Arbeit wurde bisher 131-mal zitiert (Crossref) und nennt 121 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 ( online only) for more. PURPOSE To guide use of multigene panels for germline genetic testing for patients with cancer. METHODS An ASCO Expert Panel convened to develop recommendations on the basis of a systematic review of guidelines, consensus statements, and studies of germline and somatic genetic testing. RESULTS Fifty-two guidelines and consensus statements met eligibility criteria for the primary search; 14 studies were identified for Clinical Question 4. RECOMMENDATIONS Patients should have a family history taken and recorded that includes details of cancers in first- and second-degree relatives and the patient's ethnicity. When more than one gene is relevant based on personal and/or family history, multigene panel testing should be offered. When considering what genes to include in the panel, the minimal panel should include the more strongly recommended genes from Table 1 and may include those less strongly recommended. A broader panel may be ordered when the potential benefits are clearly identified, and the potential harms from uncertain results should be mitigated. Patients who meet criteria for germline genetic testing should be offered germline testing regardless of results from tumor testing. Patients who would not normally be offered germline genetic testing based on personal and/or family history criteria but who have a pathogenic or likely pathogenic variant identified by tumor testing in a gene listed in Table 2 under the outlined circumstances should be offered germline testing. Additional information is available at www.asco.org/molecular-testing-and-biomarkers-guidelines .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingNeoplasmsGerm-Line MutationGenetic Predisposition to DiseaseHumans

Autor:innen und Institutionen

  • Beth Israel Deaconess Medical Center, Sharon, MA.
  • Keck School of Medicine of USC, Los Angeles, CA.
  • American Society of Clinical Oncology, Alexandria, VA.
  • Vall d'Hebron University Hospital, Barcelona, Spain.
  • University of Pennsylvania, Philadelphia, PA.
  • University of Michigan Rogel Cancer Center, Ann Arbor, MI.

ORCID-Profile: Nadine Tung, Hans Messersmith, Judith Balmaña, Susan Domchek, Banu Arun, Yanin Chavarri-Guerra, Stephanie A Cohen, Katherine D Crew, Michael J Hall, Gregory Idos, Ghecemy Lopez, Colin Pritchard, Huma Q Rana, Umang Swami, Gregory A Vidal

Zitieren

APA

Tung, N., Ricker, C., Messersmith, H., Balmaña, J., Domchek, S., Stoffel, E. M., Almhanna, K., Arun, B., Chavarri-Guerra, Y., Cohen, S. A., Cragun, D., Crew, K. D., Hall, M. J., Idos, G., Lopez, G., Pal, T., Pirzadeh-Miller, S., Pritchard, C., Rana, H. Q., …, & Vidal, G. A. (2024). Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. Journal of Clinical Oncology, 42(21), 2599-2615. https://doi.org/10.1200/jco.24.00662

Vancouver

Tung N, Ricker C, Messersmith H, Balmaña J, Domchek S, Stoffel EM, et al. Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline. Journal of Clinical Oncology. 2024;42(21):2599-2615. doi:10.1200/jco.24.00662

BibTeX
@article{Tung2024,
  author = {Tung, Nadine and Ricker, Charité and Messersmith, Hans and Balmaña, Judith and Domchek, Susan and Stoffel, Elena Martinez and Almhanna, Khaldoun and Arun, Banu and Chavarri-Guerra, Yanin and Cohen, Stephanie A and Cragun, Deborah and Crew, Katherine D and Hall, Michael J and Idos, Gregory and Lopez, Ghecemy and Pal, Tuya and Pirzadeh-Miller, Sara and Pritchard, Colin and Rana, Huma Q and Swami, Umang and Vidal, Gregory A},
  title = {Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {21},
  pages = {2599--2615},
  doi = {10.1200/jco.24.00662}
}
Kostenlos starten →